- Home
- REKR vs MCRB Comparison
REKR vs MCRB Comparison
Compare REKR & MCRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REKR
- MCRB
- Stock Information
- Founded
- REKR 2017
- MCRB 2010
- Country
- REKR United States
- MCRB United States
- Employees
- REKR N/A
- MCRB N/A
- Industry
- REKR Telecommunications Equipment
- MCRB Biotechnology: Pharmaceutical Preparations
- Sector
- REKR Telecommunications
- MCRB Health Care
- Exchange
- REKR Nasdaq
- MCRB Nasdaq
- Market Cap
- REKR 151.6M
- MCRB 144.8M
- IPO Year
- REKR N/A
- MCRB 2015
- Fundamental
- Price
- REKR $1.72
- MCRB $17.03
- Analyst Decision
- REKR
- MCRB Hold
- Analyst Count
- REKR 0
- MCRB 3
- Target Price
- REKR N/A
- MCRB $14.33
- AVG Volume (30 Days)
- REKR 3.6M
- MCRB 324.6K
- Earning Date
- REKR 11-13-2025
- MCRB 11-05-2025
- Dividend Yield
- REKR N/A
- MCRB N/A
- EPS Growth
- REKR N/A
- MCRB N/A
- EPS
- REKR N/A
- MCRB 0.62
- Revenue
- REKR $49,028,000.00
- MCRB $351,000.00
- Revenue This Year
- REKR $10.03
- MCRB N/A
- Revenue Next Year
- REKR $24.80
- MCRB N/A
- P/E Ratio
- REKR N/A
- MCRB $27.25
- Revenue Growth
- REKR 11.89
- MCRB N/A
- 52 Week Low
- REKR $0.62
- MCRB $6.53
- 52 Week High
- REKR $3.42
- MCRB $29.98
- Technical
- Relative Strength Index (RSI)
- REKR 34.77
- MCRB 46.97
- Support Level
- REKR $1.63
- MCRB $16.30
- Resistance Level
- REKR $2.04
- MCRB $29.98
- Average True Range (ATR)
- REKR 0.18
- MCRB 3.26
- MACD
- REKR -0.06
- MCRB -0.05
- Stochastic Oscillator
- REKR 11.16
- MCRB 20.81
About REKR Rekor Systems Inc.
Rekor Systems Inc is a United States-based company. The company is engaged in providing real-time roadway intelligence through AI-driven decisions. The firm uses artificial intelligence to analyze video streams and transform them into AI-driven decisions. The company's technology and machine learning models power all solutions, including Rekor Command for transportation management, Rekor Discover for urban mobility, and Rekor Scout for public safety, and commercial use. Its geographical segments are the United States and Others, of which a majority of its revenue comes from the United States.
About MCRB Seres Therapeutics Inc.
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.